Skip to main content

Mehdi Mirsaeidi, MD, MPH

Mehdi Mirsaeidi, MD, MPH

Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary, Critical Care,
Sleep and Allergy
University of Miami, Miller School of Medicine
Miami, Florida

Related Videos

What is the spectrum of NTM disease in the U.S., especially in patients with underlying lung disease?

What is the spectrum of NTM disease in the U.S., especially in patients with underlying lung disease?

What strategies—communication about treatment expectations, managing side effects, use of bronchodilators, etc.—do you employ at the front lines of patient management when using amikacin liposome inhalation suspension in MAC lung disease?

What strategies—communication about treatment expectations, managing side effects, use of bronchodilators, etc.—do you employ at the front lines of patient management when using amikacin liposome inhalation suspension in MAC lung disease?

What is likely to be the future burden of MAC and NTM lung disease as our populations ages?

What is likely to be the future burden of MAC and NTM lung disease as our populations ages?

Are there proven strategies for preventing NTM lung disease? If so, what are your recommendations?

Are there proven strategies for preventing NTM lung disease? If so, what are your recommendations?

When starting amikacin liposome inhalation suspension, how and for what duration do you monitor the patient for microbial conversion and response to therapy?

When starting amikacin liposome inhalation suspension, how and for what duration do you monitor the patient for microbial conversion and response to therapy?

What, in your view, are the indications and clinical phenotypes with MAC lung disease in which the FDA-approved amikacin liposome inhalation suspension is most like to achieve microbial conversion and improve clinical outcomes?

What, in your view, are the indications and clinical phenotypes with MAC lung disease in which the FDA-approved amikacin liposome inhalation suspension is most like to achieve microbial conversion and improve clinical outcomes?

Considering your high risk NTM population, what are the indications for systemic (IV) amikacin therapy, what are the limiting and concerning side effects, and what are the potential side effect-mitigating properties in patients with MAC lung disease?

Considering your high risk NTM population, what are the indications for systemic (IV) amikacin therapy, what are the limiting and concerning side effects, and what are the potential side effect-mitigating properties in patients with MAC lung disease?

Once you decide to initiate oral treatment, what regimen, in what sequence and frequency of dosing, are currently recommended? What are the expected microbial conversion rates based on the patient’s underlying disease and other risk factors?

Once you decide to initiate oral treatment, what regimen, in what sequence and frequency of dosing, are currently recommended? What are the expected microbial conversion rates based on the patient’s underlying disease and other risk factors?

In your VA Hospital setting, how do you maintain a high index of suspicion for this infection and what systemic approaches to diagnostic confirmation do you employ in this high-risk population? And what are the triggers for treatment?

In your VA Hospital setting, how do you maintain a high index of suspicion for this infection and what systemic approaches to diagnostic confirmation do you employ in this high-risk population? And what are the triggers for treatment?